{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:41:08Z","timestamp":1787586068445,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Grant-in-Aid for Young Scientists","award":["21K16317"],"award-info":[{"award-number":["21K16317"]}]},{"name":"Fostering Joint International Research grant","award":["21KK0295"],"award-info":[{"award-number":["21KK0295"]}]},{"name":"Grant-in-Aid for JSPS Fellows","award":["24KJ0091"],"award-info":[{"award-number":["24KJ0091"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["19H03458"],"award-info":[{"award-number":["19H03458"]}]},{"name":"SPS Bilateral Joint Research Projects","award":["JPJSBP120205704"],"award-info":[{"award-number":["JPJSBP120205704"]}]},{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"publisher","award":["GHIT T2021-256"],"award-info":[{"award-number":["GHIT T2021-256"]}],"id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01229-3","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T04:12:51Z","timestamp":1753503171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Malaria bivalent viral vectored vaccine protects against Plasmodium falciparum and vivax and blocks parasite transmission"],"prefix":"10.1038","volume":"10","author":[{"given":"Yutaro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sora","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Okuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Iyori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar A.","family":"Hasyim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatoshi","family":"Shida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/507S4a","volume":"507","author":"K Bourzac","year":"2014","unstructured":"Bourzac, K. Infectious disease: beating the big three. Nature 507, S4\u2013S7 (2014).","journal-title":"Nature"},{"key":"1229_CR2","doi-asserted-by":"publisher","unstructured":"Venkatesan, P. WHO World Malaria Report 2024. Lancet Microbe, 101073 https:\/\/doi.org\/10.1016\/j.lanmic.2025.101073 (2025).","DOI":"10.1016\/j.lanmic.2025.101073"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1128\/CMR.00074-12","volume":"26","author":"JK Baird","year":"2013","unstructured":"Baird, J. K. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 26, 36\u201357 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1371\/journal.pntd.0000774","volume":"4","author":"CA Guerra","year":"2010","unstructured":"Guerra, C. A. et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4, e774 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4269\/ajtmh.2001.64.97","volume":"64","author":"K Mendis","year":"2001","unstructured":"Mendis, K., Sina, B. J., Marchesini, P. & Carter, R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64, 97\u2013106 (2001).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4269\/ajtmh.1982.31.1291","volume":"31","author":"WA Krotoski","year":"1982","unstructured":"Krotoski, W. A. et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 31, 1291\u20131293 (1982).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.omtm.2022.07.016","volume":"26","author":"EL Flannery","year":"2022","unstructured":"Flannery, E. L. et al. Plasmodium vivax latent liver infection is characterized by persistent hypnozoites, hypnozoite-derived schizonts, and time-dependent efficacy of primaquine. Mol. Ther. Methods Clin. Dev. 26, 427\u2013440 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"e0007140","DOI":"10.1371\/journal.pntd.0007140","volume":"13","author":"KA Twohig","year":"2019","unstructured":"Twohig, K. A. et al. Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Negl. Trop. Dis. 13, e0007140 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4269\/ajtmh.21-0796","volume":"106","author":"CM Leonard","year":"2021","unstructured":"Leonard, C. M. et al. Missed plasmodium falciparum and plasmodium vivax mixed infections in ethiopia threaten malaria elimination. Am. J. Trop. Med. Hyg. 106, 667\u2013670 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1229_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-391","volume":"11","author":"AC Lopez","year":"2012","unstructured":"Lopez, A. C. et al. Genetic diversity of Plasmodium vivax and Plasmodium falciparum in Honduras. Malar. J. 11, 391 (2012).","journal-title":"Malar. J."},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"Rts, S. C. T. P.","year":"2015","unstructured":"Rts, S. C. T. P. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1126\/science.2414847","volume":"230","author":"DE Arnot","year":"1985","unstructured":"Arnot, D. E. et al. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230, 815\u2013818 (1985).","journal-title":"Science"},{"key":"1229_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/srep46482","volume":"7","author":"AM Salman","year":"2017","unstructured":"Salman, A. M. et al. Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Sci. Rep. 7, 46482 (2017).","journal-title":"Sci. Rep."},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3389\/fimmu.2019.02412","volume":"10","author":"Y Yusuf","year":"2019","unstructured":"Yusuf, Y. et al. A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies. Front. Immunol. 10, 2412 (2019).","journal-title":"Front. Immunol."},{"key":"1229_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005476","volume":"13","author":"M Iyori","year":"2022","unstructured":"Iyori, M. et al. Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study. Front. Immunol. 13, 1005476 (2022).","journal-title":"Front. Immunol."},{"key":"1229_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1372584","volume":"15","author":"Y Yamamoto","year":"2024","unstructured":"Yamamoto, Y. et al. A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study. Front. Immunol. 15, 1372584 (2024).","journal-title":"Front. Immunol."},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7883\/yoken.JJID.2017.458","volume":"71","author":"N Omura","year":"2018","unstructured":"Omura, N. et al. A novel system for constructing a recombinant highly-attenuated vaccinia virus strain (LC16m8) expressing foreign genes and its application for the generation of LC16m8-based vaccines against Herpes Simplex Virus 2. Jpn J. Infect. Dis. 71, 229\u2013233 (2018).","journal-title":"Jpn J. Infect. Dis."},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1099\/0022-1317-71-6-1293","volume":"71","author":"S Itamura","year":"1990","unstructured":"Itamura, S., Morikawa, Y., Shida, H., Nerome, K. & Oya, A. Biological and immunological characterization of influenza virus haemagglutinin expressed from the haemagglutinin locus of vaccinia virus. J. Gen. Virol. 71, 1293\u20131301 (1990).","journal-title":"J. Gen. Virol."},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/978-1-62703-026-7_40","volume":"923","author":"AM Blagborough","year":"2013","unstructured":"Blagborough, A. M. et al. Assessing transmission blockade in Plasmodium spp. Methods Mol. Biol. 923, 577\u2013600 (2013).","journal-title":"Methods Mol. Biol."},{"key":"1229_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02536-5","volume":"20","author":"M Cairns","year":"2022","unstructured":"Cairns, M. et al. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S\/AS01(E) vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Med. 20, 352 (2022).","journal-title":"BMC Med."},{"key":"1229_CR22","doi-asserted-by":"publisher","unstructured":"Skwarczynski, M. et al. Progress in the development of subunit vaccines against malaria. Vaccines 8 https:\/\/doi.org\/10.3390\/vaccines8030373 (2020).","DOI":"10.3390\/vaccines8030373"},{"key":"1229_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2021.102497","volume":"87","author":"S Bantuchai","year":"2022","unstructured":"Bantuchai, S., Imad, H. & Nguitragool, W. Plasmodium vivax gametocytes and transmission. Parasitol. Int 87, 102497 (2022).","journal-title":"Parasitol. Int"},{"key":"1229_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00655-5","volume":"8","author":"NJ MacDonald","year":"2023","unstructured":"MacDonald, N. J. et al. Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles. NPJ Vacc. 8, 56 (2023).","journal-title":"NPJ Vacc."},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s43856-021-00030-2","volume":"1","author":"L Kurtovic","year":"2021","unstructured":"Kurtovic, L., Reiling, L., Opi, D. H. & Beeson, J. G. Recent clinical trials inform the future for malaria vaccines. Commun. Med.1, 26 (2021).","journal-title":"Commun. Med."},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14760584.2021.1880898","volume":"20","author":"SL De","year":"2021","unstructured":"De, S. L., Ntumngia, F. B., Nicholas, J. & Adams, J. H. Progress towards the development of a P. vivax vaccine. Expert Rev. Vacc. 20, 97\u2013112 (2021).","journal-title":"Expert Rev. Vacc."},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1126\/science.2047875","volume":"252","author":"B Moss","year":"1991","unstructured":"Moss, B. Vaccinia virus: a tool for research and vaccine development. Science 252, 1662\u20131667 (1991).","journal-title":"Science"},{"key":"1229_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2022.102652","volume":"92","author":"AA Hasyim","year":"2023","unstructured":"Hasyim, A. A. et al. Adeno-associated virus-based malaria booster vaccine following attenuated replication-competent vaccinia virus LC16m8Delta priming. Parasitol. Int. 92, 102652 (2023).","journal-title":"Parasitol. Int."},{"key":"1229_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.612910","volume":"12","author":"M Shahnaij","year":"2021","unstructured":"Shahnaij, M. et al. Liver-directed AAV8 booster vaccine expressing plasmodium falciparum antigen following adenovirus vaccine priming elicits sterile protection in a murine model. Front. Immunol. 12, 612910 (2021).","journal-title":"Front. Immunol."},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1073\/pnas.0406671102","volume":"102","author":"M Kidokoro","year":"2005","unstructured":"Kidokoro, M., Tashiro, M. & Shida, H. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc. Natl. Acad. Sci. USA 102, 4152\u20134157 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1229_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/902478","volume":"2014","author":"T Ohashi","year":"2014","unstructured":"Ohashi, T., Nakamura, T., Kidokoro, M., Zhang, X. & Shida, H. Combined cytolytic effects of a vaccinia virus encoding a single chain trimer of MHC-I with a Tax-epitope and Tax-specific CTLs on HTLV-I-infected cells in a rat model. Biomed. Res. Int. 2014, 902478 (2014).","journal-title":"Biomed. Res. Int."},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/vaccines2040755","volume":"2","author":"M Kidokoro","year":"2014","unstructured":"Kidokoro, M. & Shida, H. Vaccinia virus LC16m8\u2206 as a vaccine vector for clinical applications. Vaccines2, 755\u2013771 (2014).","journal-title":"Vaccines"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"e70819","DOI":"10.1371\/journal.pone.0070819","volume":"8","author":"M Iyori","year":"2013","unstructured":"Iyori, M. et al. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One 8, e70819 (2013).","journal-title":"PLoS One"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1128\/IAI.02040-14","volume":"82","author":"M Mizutani","year":"2014","unstructured":"Mizutani, M. et al. Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect. Immun. 82, 4348\u20134357 (2014).","journal-title":"Infect. Immun."},{"key":"1229_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21369-y","volume":"8","author":"K Yoshida","year":"2018","unstructured":"Yoshida, K. et al. Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Sci. Rep. 8, 3896 (2018).","journal-title":"Sci. Rep."},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"1229_CR37","doi-asserted-by":"publisher","unstructured":"Zainal, K. H. et al. A head-to-head comparative study of the replication-competent vaccinia virus and AAV1-based malaria vaccine versus RTS,S\/AS01 in murine models. Vaccines. 12 https:\/\/doi.org\/10.3390\/vaccines12101155 (2024).","DOI":"10.3390\/vaccines12101155"},{"key":"1229_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12624","volume":"41","author":"F Amelia","year":"2019","unstructured":"Amelia, F. et al. Down-selecting circumsporozoite protein-based malaria vaccine: a comparison of malaria sporozoite challenge model. Parasite Immunol. 41, e12624 (2019).","journal-title":"Parasite Immunol."},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1016\/j.vaccine.2010.06.100","volume":"28","author":"AM Blagborough","year":"2010","unstructured":"Blagborough, A. M., Yoshida, S., Sattabongkot, J., Tsuboi, T. & Sinden, R. E. Intranasal and intramuscular immunization with baculovirus dual expression system-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28, 6014\u20136020 (2010).","journal-title":"Vaccine"},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.4049\/jimmunol.1800908","volume":"201","author":"TB Emran","year":"2018","unstructured":"Emran, T. B. et al. Baculovirus-induced fast-acting innate immunity kills liver-stage plasmodium. J. Immunol. 201, 2441\u20132451 (2018).","journal-title":"J. Immunol."},{"key":"1229_CR41","unstructured":"Guia de tratamento da mal\u00e1ria no Brasil. Minist\u00e9rio da Sa\u00fade 2\u00aa edi\u00e7\u00e3o. Bras\u00edlia-DF. (2021)."},{"key":"1229_CR42","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760200513","volume":"116","author":"C Fabbri","year":"2021","unstructured":"Fabbri, C. et al. Transmission-blocking compound candidates against Plasmodium vivax using P. berghei as an initial screening. Mem. Inst. Oswaldo Cruz 116, e200513 (2021).","journal-title":"Mem. Inst. Oswaldo Cruz"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01229-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01229-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01229-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T02:28:28Z","timestamp":1757298508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01229-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01229-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors S.Y., H.S., H.M., and M.I. are credited as inventors of patents concerning viral-vectored malaria vaccines 2022-24221. HS is also credited as an inventor on a pending patent related to LC16m8\u0394 WO 2005\/054451 A1. However, neither of these products has been brought to market. The remaining authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}